𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term prognosis of nonalcoholic fatty liver disease: Is pharmacological therapy actually necessary?

✍ Scribed by KUBILAY CINAR; SAHIN COBAN; RAMAZAN IDILMAN; ALI TUZUN; MUSTAFA SARIOGLU; MEHMET BEKTAS; ESRA ERDEN; HAKAN BOZKAYA; ALI OZDEN

Book ID
108950596
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
63 KB
Volume
21
Category
Article
ISSN
0815-9319

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Corrections: Long-term mortality in nona
Corrections: Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance?
✍ Paul Angulo πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 46 KB πŸ‘ 1 views

Data describing cirrhosis prevalence in the simple steatosis group reported in the study by Rafiq et al. should read NR (not reported) instead of 42 (56.8%). All cirrhosis prevalence proportions were calculated based upon these correct (NR) data.

Long-term efficacy of rosiglitazone in n
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
✍ Vlad Ratziu; FrΓ©deric Charlotte; Carole Bernhardt; Philippe Giral; Marine Halbro πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 365 KB πŸ‘ 1 views

Short-term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. Longer treatment might result in additional improvement. After a 1-year randomized trial, 53 patients underwent a control liver biopsy and were enrolled in an open-label extension trial